This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Oral contraceptive and risk of PE and/or DVT

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The CSM have provided evidence that the risk of venous thromboembolism associated with oral contraceptives containing norethisterone, levonorgestrel or ethynodiol increases the risk (excess risk) of venous thromboembolism by around 10 to 15 cases per 100,000 women per annum. However these studies showed that combined oral contraceptives containing desogestrel and gestodene are associated with an approximate two-fold increase in the risk, compared with those containing other progestogens.

Insufficient data was available to know whether there was an increased risk associated with combined preparations containing norgestimate.

The National Prescribing Centre have stated that (1):

  • all COCs increase the risk of venous thromboembolism (VTE). There is a small excess risk associated with COCs containing desogestrel or gestodene. However, in absolute terms, the risk is still low and is lower than the risk of VTE in pregnancy
  • on a population level, it would seem sensible to prescribe COCs that do not contain desogestrel or gestodene first-line. However, on an individual level, providing women are fully informed of the risks and do not have medical contraindications, it should be a matter of clinical judgement and personal choice as to which type of oral contraceptive is prescribed
  • all COCs should be prescribed with caution to women with a higher baseline risk of VTE
  • the riisk of VTE associated with COC use and non-use is detailed in the table below:

Circumstance

Risk of VTE per 100,000 women

Healthy, non-pregnant women (not taking any oral contraceptive)

About 5 cases per year

Women taking COCs containing levonorgestrel

About 15 cases per year of use

Women taking COCs containing desogestrel or gestodene

About 25 cases per year of use

Reference:

  1. MeReC Bulletin (2006); 17(2):1.
  2. BNF 7.3
  3. Waller P (1995). Venous thromboembolism and oral contraceptives that contain desogestrel or gestodene. CMO's Update; 8: 2.
  4. Medical Monitor (14/4/99): 13.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.